NCT02389790

Extension Study of MT-1303 in Subjects With Crohn's Disease

A Phase II, Open-label, Multicentre Study to Evaluate the Long-term Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease Who Have Completed the MT 1303-E13 Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 46 (actual)
• Sponsor: Tanabe Pharma Corporation · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The primary objectives of the study are: -To evaluate the long-term safety and tolerability of MT-1303 in subjects with moderate to severe active Crohn's Disease（CD）

Conditions

• Crohn's Disease

Interventions

Type	Name	Description
DRUG	MT-1303

Timeline

• Start date: 2015-08-01
• Primary completion: 2017-08-01
• Completion: 2017-08-01
• First posted: 2015-03-17
• Last updated: 2017-09-05

Locations

11 sites across 11 countries: Czechia, France, Germany, Hungary, Israel, Italy, Japan, Netherlands, Poland, Slovakia, Ukraine